LAT1 expression levels are correlated with adverse clinical outcomes in cancer patients, and a randomized controlled phase 2 clinical trial of LAT1 inhibitors (JPH203) is in progress in patients with advanced biliary tract cancers23. Here, SLC7A5 is linked to cancer.